Danaher Corporation
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.
What does it do?
Danaher makes the tools and equipment that scientists and doctors use behind the scenes — think the machines that help develop new drugs, test your blood, or filter water safely. If a pharmaceutical company is cooking up a new cancer treatment, there's a good chance they're using Danaher equipment to do it. The company sells things like biotech filtration systems, lab instruments, and diagnostic testing hardware to hospitals, research labs, and drug manufacturers. You've probably never heard of Danaher, but you've almost certainly benefited from something made possible by their products.
Danaher sits at the center of the global biotech and pharmaceutical supply chain — every time a new drug gets developed or a lab runs a test, Danaher likely has a piece of that process. After a brutal two-year slowdown following the COVID-19 testing and vaccine boom, investors are watching closely to see if the company can return to the strong growth it was known for before 2023. With biotech funding starting to recover and drug manufacturers restocking depleted supplies, the timing of Danaher's rebound is a major story in healthcare investing right now.
How does it make money?
Danaher makes money across three main business segments. Biotechnology — their largest segment — sells the filtration systems, cell culture media, and lab tools that drug companies need to manufacture biologics (medicines made from living cells). The Life Sciences segment sells high-end microscopes, lab instruments, and research tools to universities and pharma companies. Diagnostics covers testing equipment and consumables used in hospitals and clinics. Revenue hit $24.6 billion in the latest year, up from $23.9 billion the prior year, though much of that base was inflated by COVID-related demand that has since faded.
Why do investors care?
The core investment idea is that Danaher is a picks-and-shovels play on the growth of biotech and pharmaceuticals — meaning it profits from the boom in drug development without having to bet on any single drug succeeding. Investors have long admired Danaher's 'Danaher Business System,' an operational playbook the company uses to squeeze efficiency out of every business it acquires, which has historically made it one of the best compounders on the market. The big question right now is whether biotech customers have finished burning through excess inventory built up during COVID, which would unlock a fresh wave of orders. If pharma spending picks back up and GLP-1 drug manufacturing scales aggressively, Danaher is one of the biggest indirect beneficiaries.
Deep Dive
MemberA full investor briefing on Danaher Corporation — history, leadership, risks, and outlook.